Neurocrine Biosciences (NASDAQ:NBIX) Insider Darin Lippoldt Sells 9,800 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 9,800 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $170.16, for a total transaction of $1,667,568.00. Following the completion of the transaction, the insider directly owned 54,729 shares in the company, valued at $9,312,686.64. This trade represents a 15.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt also recently made the following trade(s):

• On Friday, June 26th, Darin Lippoldt sold 200 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $169.56, for a total transaction of $33,912.00.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $168.54 on Wednesday. The company has a market cap of $16.95 billion, a P/E ratio of 25.97, a P/E/G ratio of 0.68 and a beta of 0.40. The firm’s fifty day moving average is $153.53 and its two-hundred day moving average is $141.34. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $171.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NBIX. Basecamp Wealth Advisors LLC grew its holdings in Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after purchasing an additional 204 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Neurocrine Biosciences by 471.3% in the 1st quarter. Pacer Advisors Inc. now owns 169,230 shares of the company’s stock worth $22,294,000 after purchasing an additional 139,609 shares in the last quarter. Carmignac Gestion boosted its position in shares of Neurocrine Biosciences by 192.5% in the 1st quarter. Carmignac Gestion now owns 186,000 shares of the company’s stock worth $24,504,000 after purchasing an additional 122,400 shares in the last quarter. Defilade Capital Management L.P. purchased a new position in Neurocrine Biosciences during the 1st quarter worth $27,656,000. Finally, Parallel Advisors LLC grew its stake in Neurocrine Biosciences by 12.3% during the 1st quarter. Parallel Advisors LLC now owns 1,776 shares of the company’s stock worth $234,000 after buying an additional 195 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on NBIX. Royal Bank Of Canada upped their price objective on Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Wedbush boosted their target price on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 24th. Canaccord Genuity Group raised their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Finally, Morgan Stanley lifted their price objective on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $187.52.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.